No, but my understanding is that Prof Ming-Hao
Zeng, who is Orthocell’s CSO and largest
shareholder pioneered both ATI and Celgro and
also Vericel’s MACI.
Big difference is, that Vericel have turned MACI
into a very lucrative money earner( expected
to return between $130M and $140M for 2022),
and OCC are nowhere near commercialising
ATI.
Ann: OrthoATI Rotator Cuff Study Success With Cross-Over Patients, page-33
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
60.0¢ |
Change
0.050(9.09%) |
Mkt cap ! $125.7M | |||
| Open | High | Low | Value | Volume |
| 56.5¢ | 60.5¢ | 56.5¢ | $412.0K | 699.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3608 | 59.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.0¢ | 44783 | 3 |
View Market Depth
| Last trade - 10.47am 10/10/2024 (20 minute delay) ? |
| OCC (ASX) Chart |